Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
Table 2
Population pharmacokinetics at Week 48 (univariate analysis).
Darunavir
Etravirine
Median (range) Ng·h/mL
Median (range) ng/mL
Median (range) ng·h/mL
Median (range) ng/mL
Overall population
376
60,642 (26,117–128,790)
3624 (931–9570)
190
4183 (212–27,960)
280 (4–2211)
Age, years
≤30
39
58,309 (33,050–128,790)
3317 (1145–9570)
17
3476 (568–5261)
212 (5–331)
>30 to ≤50
260
59,955 (26,117–105,130)
3584 (931–6841)
128
4348 (212–27,960)
286 (4–2211)
>50 to ≤65
68
64,337 (40,299–120,880)
3957 (2215–8906)
38
4366 (295–11,684)
291 (11–890)
>65
9
63,978 (38,171–84,295)
3916 (1879–5869)
7
7484 (2213–17,921)
541 (126–1392)
Weight at baseline, kg
≤62.33
94
61,005 (32,271–128,790)
3665 (1169–9570)
46
3675 (295–17,921)
226 (11–1392)
>62.33 to ≤73.94
96
58,367 (29,888–93,408)
3489 (931–6081)
48
3824 (1004–20,495)
250 (42–1605)
>73.94 to ≤87.09
92
63,942 (34,692–105,130)
3903 (1568–6502)
52
4960 (212–27,960)
332 (4–2211)
>87.09
94
61,090 (26,117–100,710)
3561 (1258–6943)
44
4638 (1319–18,977)
314 (60–1487)
Hepatitis B co-infection status
No
362
60,831 (26,117–128,790)
3618 (931–9570)
184
4141 (212–27,960)
278 (4–2211)
Yes
14
57,936 (37,506–97,125)
3718 (1640–6784)
6
5504 (3751–11,684)
382 (241–890)
Use of TDF
No
58
61,443 (38,104–109,410)
3489 (1169–7473)
45
5051 (295–17,921)
329 (11–1392)
Yes
318
60,601 (26,117–128,790)
3627 (931–9570)
145
3998 (212–27,960)
258 (4–2211)
Use of etravirine
No
187
58,933 (26,117–128,790)
3489 (1036–9570)
NA
NA
NA
Yes
189
62,626 (30,960–109,410)
3806 (931–7473)
NA
NA
NA
: area under the plasma concentration–time curve over 12 hours; : trough concentration; TDF: tenofovir disoproxil fumarate; NA: not applicable.
